In pancreatic cancer, HLA‐B modulates ITGB1 expression, influencing migration and transmembrane signaling [82], while its altered expression impairs tumor antigen recognition in cervical cancer [83] and affects immune checkpoint inhibitor efficacy in gastrointestinal malignancies [84]. This evidence concerns the gene HLA-B and cervical cancer.